Family Medicine · Broomall, PA
NPI
1053315523
Since 2005
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1999 Sproul Rd, Ste 21
Broomall, PA, 19008
Phone (610) 353-5840
Groups this clinician bills Medicare through
Medicare paid, 2024
$123K
1,712 services
Medicare patients, 2024
421
Average age 74
Drug cost, 2024
$1.8M
23,771 prescriptions
Company payments, 2025
$3,327
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph Labricciosa was code 99213 (office e&m - established), 723 times for 315 patients. In total Joseph Labricciosa billed 1,712 services in 30 codes, and Medicare paid $123K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 723 | 315 | $61.92 | $45K |
| 99214 Office E&M - Established | Office | 219 | 157 | $94.05 | $21K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 210 | 210 | $132.76 | $28K |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 84 | 84 | $19.45 | $1,634 |
| G0008 Administration of influenza virus vaccine | Office | 74 | 74 | $33.29 | $2,463 |
| 90662 Vaccine Product | Office | 72 | 72 | $81.68 | $5,881 |
| 99212 Office E&M - Established | Office | 71 | 58 | $35.79 | $2,541 |
| G0442 Annual alcohol misuse screening, 5 to 15 minutes | Office | 69 | 69 | $19.45 | $1,342 |
| 96372 Injection Administration | Office | 24 | 14 | $10.22 | $245 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 20 | 18 | $228.19 | $4,564 |
| 93000 Electrocardiogram | Office | 19 | 18 | $11.74 | $223 |
| 99495 Chronic, Principal, and Transitional Care Management | Office | 18 | 17 | $158.81 | $2,859 |
| G0402 Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 15 | 15 | $168.74 | $2,531 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 11 | 11 | $39.51 | $435 |
By year: 2022 $136K for 1,796 services; 2023 $123K for 1,637 services; 2024 $123K for 1,712 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joseph Labricciosa prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,040 prescriptions and refills. In total Joseph Labricciosa wrote 23,771 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,040 | 1,642 | 109 | $10K |
| Metoprolol Succinate Generic | 931 | 1,459 | 110 | $11K |
| Atorvastatin Calcium Generic | 846 | 1,520 | 113 | $9,941 |
| Amlodipine Besylate Generic | 816 | 1,449 | 113 | $5,867 |
| Rosuvastatin Calcium Generic | 809 | 1,409 | 111 | $11K |
| Furosemide Generic | 684 | 853 | 81 | $2,887 |
| Pantoprazole Sodium Generic | 637 | 973 | 81 | $6,033 |
| Hydrochlorothiazide Generic | 633 | 1,111 | 85 | $3,692 |
| Potassium Chloride Generic | 575 | 644 | 47 | $6,366 |
| Gabapentin Generic | 533 | 622 | 49 | $3,875 |
| Losartan Potassium Generic | 477 | 728 | 50 | $5,265 |
| Xarelto Rivaroxaban | 395 | 411 | 17 | $85K |
| Metformin Hcl Generic | 385 | 844 | 79 | $2,993 |
| Omeprazole Generic | 379 | 635 | 49 | $3,515 |
| Simvastatin Generic | 342 | 622 | 47 | $2,799 |
Brand drugs: 3,065 claims; generic drugs: 20,616 claims; opioid claims: 366.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph Labricciosa $3,327 ($3,327 in general payments such as food, travel and fees) from 29 companies. The largest payer was Abbvie Inc. with $486.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 23 | $486 |
| Axsome Therapeutics, Inc. AXSM | 13 | $381 |
| Pfizer Inc. PFE | 14 | $340 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $205 |
| GlaxoSmithKline, LLC. GSK | 8 | $166 |
| Astellas Pharma US Inc 4503.T | 4 | $113 |
| Novo Nordisk Inc NVO | 5 | $110 |
| Aimmune Therapeutics, Inc. | 4 | $103 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 6 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 5 | $97.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.